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Tobacco use in developed countrieshas been estimated can cause some desensitization without activation be-
cause the desensitized receptor has a higher affinity forto cause nearly 20% of all deaths, making it the largest
single cause of premature death (Peto et al., 1992). The agonist than the resting or open receptor. In addition,
there is evidence that neuronal nAChRs can exist ondrive for tobacco by humans is clear. The majority of
smokershave tried repeatedly to quitand failed. In about the cell surface as nonfunctional receptors (Margiotta
et al., 1987) or can enter long-lived inactivated states80% of the attempts to quit, smokers return to tobacco
in less than 2 years (Schelling, 1992). Although the un- (Lester and Dani, 1994).
The higher affinity of the desensitized receptor forderlying mechanisms that cause tobacco abuse are not
wellunderstood, theaccumulation of evidence indicates agonist and the changing distribution of nAChRs among
the various functional states must be considered to un-that nicotine is the primary component of tobacco that
motivates continued use despite harmful effects (Schel- derstand what takes place during sustained nicotine
use. A knowledge of long-term forms of inactivation mayling, 1992; Stolerman and Shoaib, 1991).
Nicotine alone, free of smoke or associated factors, be especially important for understanding the phases
of withdrawal symptoms and the development of toler-can elicit drug-seeking behavior in animal studies as
demonstrated by self-administration and place prefer- ance to nicotine. Aspects of tolerance and withdrawal
could be explained by nicotinic receptors slowly recov-ence experiments (Stolerman and Shoaib, 1991; Corri-
gall and Coen, 1989). Intravenous self-administration of ering to functional states from various levels of desensi-
tization and inactivation.nicotine is best demonstrated under conditions of lim-
ited availability; rats have higher lever-pressing rates Pathways of Reward in Nicotine Abuse
A multiplicity of psychopharmacological effects contrib-when nicotine is delivered intermittently rather than con-
tinuously (Goldberg and Henningfield, 1988). The re- ute to the reinforcing actions of drugs. A widely ac-
cepted hypothesis is that drugs of abuse commandeersponding rate to nicotine is dose dependent, falling off
at both lower and higher concentrations. Responding existing reward pathways that are normally essential for
survival. The mesolimbic dopaminergic system is knownrates sometimes continue until rats experience toxic
effects. At these and higher concentrations, nicotine to have an important role in mediating reward and contri-
butes to the rewarding effects of cocaine and d-amphet-causes vomiting, tremors, convulsions, and death at
extreme doses. The onset of aversive effects can com- amine (Koob, 1992). Cocaine, for instance, is thought
to act by inhibiting the DA transporter; knockout miceplicate the reinforcing effectiveness of nicotine when
compared with other drugs, which serve as reinforcers lacking the DA transporter are unaffected by the admin-
istration of cocaine (Giros et al., 1996). The most impor-over a wider range of test situations. The evidence is
clear, however, that like other addictive drugs, nicotine tant dopamine (DA) pathway originates in the ventral
tegmental area (VTA) of the midbrain and projects toreinforces self-administration, increases locomotor ac-
tivity, enhances reward from brain stimulation, and rein- forebrain structures including the prefrontal cortex and
to limbic areas such as the olfactory tubercle, the amyg-forces place preference (Clarke, 1991; Goldberg and
Henningfield, 1988; Stolerman and Shoaib, 1991). dala, the septal region, and the nucleus accumbens. A
range of studies using DA agonists and antagonists andNicotinic Acetylcholine Receptors as the
Primary Site of Nicotine Action behavioral studies on the self-administration of drugs
after destruction of mesolimbic neurons have led to theIt is likely that nicotinicacetylcholine receptors (nAChRs)
are the initial sites of action for nicotine obtained from conclusion that DA release in the nucleus accumbens
is ªrewardingº or represents an encounter with rewardtobacco. Understanding nicotine abuse will require
some knowledge of how these receptors function within from the environment.
There is direct evidence that nicotine acts upon thethe neuronal pathways that are relevant to addiction. A
nAChR normally binds acetylcholine (ACh) and under- mesolimbic pathways. Autoradiography and in situ hy-
bridization indicate that multiple nAChR a and b sub-goes a conformational change that opens a cation-se-
lective channel for several milliseconds. Subsequently, units are present throughout these areas (Marks et al.,
1992; McGehee and Role, 1995; Wada et al., 1989). VTAthe ion channel closes, and the receptor may be refrac-
tory to agonist for many milliseconds or more. neurons have nAChRs located on their cell bodies and
on their terminals in the nucleus accumbens. Intermit-Evidence from a variety of sources indicates that nico-
tinic receptors can exist in many different functional tently administered nicotinic receptor agonists directly
excite VTA neurons, but during long exposure, the influ-states (Figure 1; Changeux et al., 1984). Nicotinic recep-
tors are largely in a closed (resting) state before agonist ence of the nicotinic agonists decreases (Calabresi et
al., 1989). Nicotine stimulates the release of DA in thearrives, are briefly in an open state while the channel is
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increase. An increased number of nAChRs is not a re-
sponse that might at first be expected because chronic
exposure to an agonist usually produces excessive re-
ceptor activation; homeostasis is then achieved by
down-regulation of the receptors. Likewise, chronic ex-
posure to an antagonist produces receptor up-regula-
tion in many systems. These forms of self-regulation are
presumably mechanisms to maintain relatively normal
synaptic transmission and brain function in thepresence
of abnormal receptor activity induced by endogenous
or exogenous agonists or antagonists.
A reasonable explanation for the unexpected increase
in nAChRs is that low levels of nicotine cause signifi-
cant receptor desensitization, and over the long term,
nAChRs enter long-lasting inactive states (Lester and
Dani, 1994; Peng et al., 1994; Wonnacott, 1990). These
changes would enable some cholinergic systems to
move toward their initial levels of excitability even as
Figure 1. A Representation of Functional States of a nAChR the number of nAChRs increases due to chronic nicotine
The diagram represents a kinetic model, in which A is the agonist, exposure. Direct support for this idea is provided by
R is the resting or responsive state of the receptor, O is the ion- the finding that high doses of the nAChR antagonist
conducting open state of the channel, D is a desensitized state, D9
mecamylamine also cause an increased number ofis a deeper-level desensitized state, and I is an inactivated state.
nAChRs. There is evidence that the number of surfaceChronic exposure to the agonist nicotine could induce additional,
longer-lasting inactivated states. The arrows represent possible receptors increases when nAChRs enter particular unre-
transitions between states. The states in the top row leading to O sponsive states. Interestingly, the number of nicotinic
are visited for short times, and the open state lasts a few millisec- receptors seems to be regulated by a posttranscrip-
onds. The transitions between the rows of states can be much
tional mechanism that decreases nicotinic receptor turn-slower. Good estimates are not available for the lifetimes of the
over (Peng et al., 1994); the level of nAChR mRNA doesinactive states. Those states could last minutes or hours; the deeper
not seem to change (Marks et al., 1992).states of inactivation could last for days or could be essentially
irreversible. The population distribution of the states depends on In summary, there is support for the following model:
many factors, especially the agonist concentration and the rate of chronic exposure to low levels of nicotine induces
application. The model is not intended to represent all the possible inactivation of some nAChRs, which then turn over
modifications or kinetic properties or subtype diversity of nAChRs. more slowly (Peng et al., 1994). Consequently, the num-
ber of nicotinic receptors on the surface of the mem-
nucleus accumbens of freely moving rats and stimulates brane increases. Depending on cholinergic activity and
release from synaptosomes isolated from various areas changes in nicotine concentration in the brain, these
including the nucleus accumbens (Clarke, 1991). Finally, nAChRs will distribute among the various functional
the role of the mesolimbic system in nicotine abuse is states: resting, open, short-term desensitized, and long-
supported by the findings that DA antagonists or lesions term inactivated. Different nAChR subtypes and particu-
of the nucleus accumbens reduce nicotine self-adminis- lar cholinergic systems would be expected to recover
tration in rats (Corrigall et al., 1992; Stolerman and from inactivation to responsive states at different rates.
Shoaib, 1991). Although nAChR desensitization and inactivation
It must be kept in mind, however, that there are other may underlie the increase in nAChRs, the cholinergic
reward pathways and that other compounds in tobacco systems are probably not relaxing back to the initial
may affect the reward. For instance, monoamine oxi- condition present before nicotine exposure. In some
dase B (MAOB), which participates in the degradation cases, cholinergic sensitivity has been shown to in-
of DA, is partially inhibited in the brains of smokers crease after the number of nicotinic sites increases.
(Fowler et al., 1996). Although inhibitors of MAOB do For example, in rats after chronic treatment, nicotine
not seem to have addictive potency, the increased avail- induces greater magnitudes of conditioned placed pref-
ability of DA to chronic smokers arising from MAOB erence and evokes greater DA release from striatal syn-
inhibition could enhance the addictive power of nicotine. aptosomes (Shoaib et al., 1994; Wonnacott, 1990). In
Furthermore, otherpathways involved in reward, in addi- other cases, however, cholinergic efficacy decreases.
tion to the mesolimbic pathway, could be affected di- After chronic nicotine, a single pulse of nicotine induces
rectly and indirectly by nicotine, possibly contributing less prolactin release (Hulihan-Gublin et al., 1990),
to a myriad of reinforcing effects and learned behaviors. evokes a smaller behavioral response in mice, and
Chronic Nicotine Use Increases evokes less DA release from mouse striatal synapto-
the Number of nAChRs somes (Marks et al., 1993). These differences could arise
In addition to the possibility of an immediate effect on from various factors. One factor might be multiphasic
the functional states of nAChRs, long-term nicotine ex- recovery from inactivation by distinct nAChR subtypes
posure causes an increase in the actual number of in separate areas of the brain. There are many subtypes
nAChRs in humans, mice, and rats (Marks et al., 1992; of nAChRs that respond differently to agonists
Wonnacott, 1990). This increase is specific to nicotinic (McGehee and Role, 1995). Theoretically, there could
be a range of relaxation times as the various nAChRAChRs. Muscarinic ACh receptors, for instance, do not
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subtypes distribute among functional states in response
to the changing concentration of nicotine.
Effect of Nicotine Delivered By Smoking
A basic question in the study of nicotine abuse is how
much nAChR activation and inactivation is caused by
a smoker's level of nicotine (Clarke, 1991; Wonnacott,
1990). A smoker can deliver small pulses of nicotine
into the arterial blood in the range of about 0.5 mM
(Henningfield et al., 1993). It is appealing to speculate
that nicotine may be abused because the small peaks
of nicotine associated with each cigarette can activate
nAChRs and cause DA release. This activity leading to
DA release and an associated reward could be the main
mechanism that initiates nicotine abuse.
It also must be considered, however, that the peaks
of nicotine associated with each cigarette are superim-
posedon a steady-state nicotine level of z0.1 mM, which Figure 2. A Hypothetical Cycle for Perpetuating Nicotine Use
increases with repeated cigarette consumption during The increased number of nAChRs and the subsequent pathology
the day because nicotine has a long half-life of about 2 of nicotinic cholinergic function is hypothesized to develop after
chronic use of nicotine. The simplified scheme is described inhr (Benowitz et al., 1989; Russell, 1989). There is evi-
the text.dence that steady levels of nicotine can cause signifi-
cant desensitization because, after one nicotine dose,
there develops an acute tolerance to a second dose drive for nicotine because the antagonist would be ex-
following within an hour. pected to inactivate the excess pool of functional
Hypothesis for Sustained Nicotine Use nAChRs.
It is possible that nicotine-induced release of DA drives This model of nicotine addiction can be tested in more
tobacco usage, while inactivation of nAChRs by low detail by studying the activation and desensitization
levels of nicotine may play a role in the processes of mechanisms induced by nicotine. A number of other
tolerance and withdrawal. Presumably a regular smoker questions need further investigation. What is the role
has an excess number of nAChRs, but at the same time, of the many nicotinic receptor subtypes? Do specific
the smoker maintains a low level of nicotine that may nAChR subtypes mediate addiction? Is nicotine addic-
inactivate many of the nAChRs. After many hours of tion mediated directly by the same reward pathways
abstinence (such as overnight), a smoker's nicotine lev- involved in other drug addictions? Does chronic nicotine
els fall and the inactivated nAChRs begin to recover to induce long-term changes in the mesolimbic dopamin-
a responsive state with a rate that may be dependent ergic system beyond the increased number of nAChRs
on the receptor subtype. As an excessive number of
that have been seen in many areas of thebrain, including
nAChRs become responsive, there might be heightened
the ventral tegmental area and the nucleus accumbens?
or abnormal potentiation of ordinary synaptic activity
Simplified Summary
in some nonrewarding cholinergic pathways that could
A simplistic hypothesis can be put forward as a working
contribute to theagitation and discomfort (or withdrawal
basis for research (Figure 2). Upon smoking a cigarette,symptoms) that drive the smoker to the next cigarette.
a small pulse of nicotine activates nAChRs that directlyThat next dose of nicotine would have at least two
or indirectly induce DA release that provides a pleasur-effects. First, after a night time of abstinence, a dose of
able effect. It is likely that the mesolimbic dopaminergicnicotine could be more rewarding than normal, either
system mediatesat least part of this reward. With contin-by directly causing DA release within the mesolimbic
ued use, nicotine builds up to a low steady-state con-system or by acting elsewhere on other pathways that
centration that causes significant nAChR desensitiza-provide reward or by indirectly activating reward path-
tion and (over time) longer-term inactivation. There isways. This hypothesis is supported by reports from
evidence that nicotinic receptor turnover decreases fol-smokers that they receive the most pleasurable impact
lowing inactivation, leading to an increased number offrom the first cigarette of the day (Russell, 1989). Sec-
nAChRs, which subsequently may lead to nicotinic cho-ond, after the initial reward (nicotine dose), a longer term
linergic systems that are pathological. In between ciga-effect of subsequent cigarettes (nicotine doses) could
rettes, during sleep, or under conditions of abstinencebe to desensitize the excess number of nAChRs back
while attempting to stop smoking, nicotine levels dropto their usual state of inactivation for a regular smoker.
and a portion of the inactive nAChRs recover to a re-Thus, smokers report a relief from agitation and tension
sponsive state. Because of the increased number ofafter they have consumed nicotine. This relief from with-
nAChRs that have now become responsive in this patho-drawal symptoms could be explained as follows: nico-
logical condition, some cholinergic systems other thantine desensitizes the excess number of responsive
the reward pathways become hyperexcitable to synapti-nAChRs in nonreward pathways back to a lower more
cally released ACh, contributing to the drive for the nextappropriate number of functional receptors for the
cigarette. Thus, smokers medicate themselves with nic-smoker. This hypothesis is supported by the finding that
otine to regulate the number of functional nAChRs.nAChR antagonists can suppress drug-seeking behav-
Superimposed on this simplistic cycle of nicotine ex-ior (Corrigall and Coen, 1989; Corrigall et al., 1992; Gold-
berg and Henningfield, 1988), possibly decreasing the posure, there may be long-term synaptic changes that
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result in the learned behaviors that are associated with
smoking and with the context in which smoking takes
place. Because these behaviors are reinforced by re-
peated variable rewards from cigarettes (especially after
abstinence) and by associated sensory cues, the desire
for cigarettes extinguishes slowly and sometimes in-
completely. These factors coupled to the easy access
of cigarettes and constant advertising contribute to the
difficulty in breaking the nicotine habit.
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